Secondary Stock OfferingsBy The Online Investor Staff, updated Thu., Feb. 27, 3:44 PM
|This Slide: #22 of 25|
Slide #22. Seelos Therapeutics, Inc. — Secondary Offering
Seelos Therapeutics, Inc. (NASDAQ:SEEL)
Date of Pricing:
Price Per Share:
Secondary Offering Details:
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the pricing of an underwritten public offering of 6,666,667 shares of its common stock, at a price to the public of $0.75 per share. In addition, the Company granted the underwriters a 45-day option to purchase up to 999,999 additional shares of its common stock to cover over-allotments, if any. All of the shares of common stock in the offering are being sold by Seelos.
Seelos Therapeutics is a biopharmaceutical company focused on the development of technologies and therapeutics for the treatment of central nervous system, respiratory and other disorders. Co.'s primary programs are SLS-002, SLS-005 and SLS-006. SLS-002 is intranasal racemic ketamine with two investigational new drug applications, for the treatment of suicidality in post-traumatic stress disorder, and in main depressive disorder. SLS-005, is Trehalose, a protein stabilizer that also activates autophagy and crosses the blood-brain-barrier. Co. is developing Trehalose for the treatment of Sanfilippo syndrome. SLS-006 is a true partial dopamine agonist for Parkinson's disease patients.
Open the SEEL Page at The Online Investor »
Strong Buy (4.00 out of 4)
(ranked higher than approx. 83% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite